Roth Capital Issues Negative Forecast for biote Earnings

biote Corp. (NASDAQ:BTMD) – Equities researchers at Roth Capital decreased their Q3 2025 earnings estimates for biote in a research report issued to clients and investors on Thursday, August 7th. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.06 for the quarter, down from their previous estimate of $0.13. The consensus estimate for biote’s current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote’s Q4 2025 earnings at $0.09 EPS, Q1 2026 earnings at $0.09 EPS, Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.11 EPS and Q4 2026 earnings at $0.14 EPS.

biote (NASDAQ:BTMD) last issued its earnings results on Wednesday, August 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.04. biote had a net margin of 15.73% and a negative return on equity of 19.71%. The firm had revenue of $48.86 million for the quarter, compared to analysts’ expectations of $49.52 million.

BTMD has been the topic of a number of other research reports. B. Riley cut biote from a “buy” rating to a “neutral” rating and cut their price target for the company from $8.00 to $4.00 in a report on Thursday. Wall Street Zen cut biote from a “strong-buy” rating to a “hold” rating in a report on Saturday.

biote Stock Down 1.4%

Shares of NASDAQ BTMD opened at $2.88 on Friday. The firm’s 50-day moving average price is $4.00 and its two-hundred day moving average price is $4.03. The stock has a market capitalization of $157.56 million, a P/E ratio of 3.20 and a beta of 1.21. biote has a 52-week low of $2.87 and a 52-week high of $6.98.

Hedge Funds Weigh In On biote

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its position in biote by 15.0% during the 1st quarter. Acadian Asset Management LLC now owns 700,871 shares of the company’s stock worth $2,330,000 after purchasing an additional 91,672 shares in the last quarter. Dimensional Fund Advisors LP grew its position in biote by 0.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock worth $4,211,000 after purchasing an additional 3,065 shares in the last quarter. Geode Capital Management LLC grew its position in biote by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 616,697 shares of the company’s stock worth $2,480,000 after purchasing an additional 41,333 shares in the last quarter. Northern Trust Corp grew its position in biote by 9.9% during the 4th quarter. Northern Trust Corp now owns 288,336 shares of the company’s stock worth $1,782,000 after purchasing an additional 25,873 shares in the last quarter. Finally, Nuveen LLC purchased a new position in biote during the 1st quarter worth approximately $872,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.